Citius Oncology, Inc. (CTOR) vs Equillium, Inc. (EQ)

A side-by-side comparison of Citius Oncology, Inc. and Equillium, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Citius Oncology, Inc. logo
CTOR
Citius Oncology, Inc.
$82M
$0.88HealthcareDelayed quote: Oct 6, 2026, 10:17 AM EDT
Equillium, Inc. logo
EQ
Equillium, Inc.
$89M
$1.40HealthcareDelayed quote: Oct 6, 2026, 10:24 AM EDT

Total return — CTOR vs EQ

growth of $100 · dividends reinvested · last 2y
CTOR -92.4% (-72.4%/yr)EQ +66.7% (+29.1%/yr)EQ compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020252026$8$167
CTOR EQ

CTOR vs EQ: by the numbers

  • •EQ is the larger company ($89M vs $82M market cap).
  • •Both run net losses; EQ's is the smaller (0.00% vs -648.32% net margin).

Metrics side by side

Valuation

MetricCTOREQ
Forward P/E8.80N/A
P/S ratio11.52N/A
P/B ratio2.031.58

Profitability

MetricCTOREQ
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin-648.32%0.00%
ROE-114.06%-32.15%
ROIC-88.72%-34.10%

Growth (annualized)

MetricCTOREQ
Total return CAGR (5Y)N/A-26.99%

Go deeper

Full CTOR analysisFull EQ analysisInteractive comparison tool

Dig into the metrics

Citius Oncology ROEEquillium ROECitius Oncology operating marginEquillium operating marginCitius Oncology revenue growthEquillium revenue growthCitius Oncology free cash flowEquillium free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.